Table 2

Comorbid diagnoses of non-users and users of hypnotics (percentages of total group)

ComorbidityNon-usersAny hypnotic usersZolpidemTemazepam
Asthma***6.611.310.911.3
Cerebrovascular disease***3.86.25.96.1
Coronary heart disease***9.414.514.115.8
Chronic kidney disease***0.91.71.51.9
COPD***5.59.18.88.8
Cardiovascular disease, all***14.121.421.122.3
Dementia0.60.60.70.2
Diabetes***14.617.917.818.5
Heart failure***3.26.66.66.6
Hypertension***37.542.841.943.9
Obesity***6.710.59.610.0
Reflux and peptic disease***15.027.926.926.3
Peripheral vascular disease***2.13.94.03.7
  • The percentages with each class of comorbidity diagnoses are shown for non-users and users of hypnotics. Among users, specific comorbidity percentages are shown for those prescribed only zolpidem or only temazepam. Comorbidity classes are further defined in supplemental table 2.

  • ***Indicates p<0.001, contrasting non-users versus all hypnotic users.